Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2022-10-04 Regulatory Filings
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, specifically an Amendment No. 1 to a previously filed 8-K. It reports the completion of a merger and provides financial information related to the merger, including unaudited pro forma condensed combined financial information and interim financial statements. The document references exhibits containing financial data but itself is a regulatory filing to update investors on a material event (merger completion and related financial info). It does not contain a full annual or quarterly report, nor is it a presentation or earnings release. The document is about a specific event and related financial disclosures, typical of a Current Report (8-K). According to the classification rules, such filings are best categorized under Regulatory Filings (RNS) as they are general regulatory announcements that do not fit other specific categories like Annual Report or Interim Report. The document length is just over 5,000 characters, but it is primarily an 8-K amendment with financial exhibits incorporated by reference, not the full financial report itself. Therefore, the best classification is Regulatory Filings (RNS).
2022-10-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 29, 2022. It discusses a Nasdaq deficiency letter regarding the company's stock price falling below the minimum bid price requirement and subsequent notification that the company regained compliance. The content is an update on a regulatory compliance matter related to listing standards, not a full financial report or earnings release. The document length is 3813 characters, which is relatively short and primarily serves as a regulatory announcement. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update rather than a detailed financial report or other specific filing type.
2022-09-29 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act, amending and supplementing a previously filed prospectus and prospectus supplement related to an At The Market (ATM) offering of common stock. It discusses the terms of the offering, the aggregate offering price limits, and references the Registration Statement on Form S-3. The document is focused on capital raising activities and updates to the offering details rather than financial results, management changes, or other report types. It is not a full financial report, earnings release, or regulatory certification. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive offering details, not just an announcement of a report, so it is not an RPA or RNS. Confidence is high given the clear nature of the document as a prospectus supplement related to capital raising.
2022-09-26 English
8-K
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 22, 2022, by Lisata Therapeutics, Inc. It includes a Regulation FD Disclosure of a slide presentation attached as Exhibit 99.1, described as a corporate presentation for investor and industry conferences. The content discusses clinical trial updates and strategic considerations but does not contain detailed financial statements or comprehensive financial analysis. The primary purpose is to furnish a presentation for investors and industry participants, which aligns with the definition of an Investor Presentation (IP). The document length is 5266 characters, sufficient to include substantive content, and it is not merely an announcement of a report publication. Therefore, the classification is Investor Presentation (IP).
2022-09-22 English
FORM 3
Director's Dealing
2022-09-16 English
FORM 3
Director's Dealing
2022-09-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.